Raltitrexed (Tomudex®): An alternative choice in patients intolerant to 5-fluorouracil

Sanford Kempin, Jorge Gutierrez, Elizabeth Wilson, Colin Lowery, Robert Diasio

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Raltitrexed (Tomudex®), a classical folate antagonist, is a selective inhibitor of thymidylate synthase (TS). It has significant single-agent activity in metastatic colorectal cancer. Severe life-threatening toxicity related to the administration of 5-fluorouracil and leucovorin is described in two patients, both of whom were not deficient in dihydropyrimidine dehydrogenase. Raltitrexed was administered to both patients with clinically acceptable side effects and allowed a TS inhibitor to be administered as part of an adjuvant program.

Original languageEnglish (US)
Pages (from-to)992-995
Number of pages4
JournalCancer Investigation
Volume20
Issue number7-8
DOIs
StatePublished - 2002

Keywords

  • An alternative
  • Intolerance to 5-fluorouracil
  • Raltitrexed (Tomudex®)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Raltitrexed (Tomudex®): An alternative choice in patients intolerant to 5-fluorouracil'. Together they form a unique fingerprint.

  • Cite this